{"version":3,"file":"fallbackInteractions-ByRSxiMM.js","sources":["../../src/data/fallbackInteractions.ts"],"sourcesContent":["// Fallback curated interactions data for when API is not available\nexport const FALLBACK_INTERACTIONS = [\n  {\n    drugs: ['aspirin', 'warfarin'],\n    severity: 'major',\n    mechanism: 'Additive anticoagulant/antiplatelet effects',\n    effect: 'Significantly increased bleeding risk',\n    management: 'Avoid combination or monitor very closely; frequent INR checks',\n    evidence_level: 'A',\n    sources: ['Clinical literature', 'FDA guidelines']\n  },\n  {\n    drugs: ['oxycodone', 'ketoconazole'],\n    severity: 'major',\n    mechanism: 'CYP3A4 inhibition increases oxycodone exposure',\n    effect: 'Enhanced sedation and respiratory depression',\n    management: 'Avoid or reduce oxycodone dose; monitor closely',\n    evidence_level: 'B',\n    sources: ['FDA']\n  },\n  {\n    drugs: ['fentanyl', 'clarithromycin'],\n    severity: 'major',\n    mechanism: 'CYP3A4 inhibition increases fentanyl levels',\n    effect: 'Risk of fatal respiratory depression',\n    management: 'Avoid combination; consider alternative antibiotic',\n    evidence_level: 'A',\n    sources: ['FDA']\n  },\n  {\n    drugs: ['methadone', 'amiodarone'],\n    severity: 'major',\n    mechanism: 'Additive QT prolongation',\n    effect: 'Torsades de pointes risk',\n    management: 'Avoid combination; ECG monitoring if unavoidable',\n    evidence_level: 'B',\n    sources: ['Cardiology guidelines']\n  },\n  {\n    drugs: ['warfarin', 'ciprofloxacin'],\n    severity: 'moderate',\n    mechanism: 'CYP1A2/3A4 inhibition increases warfarin exposure',\n    effect: 'Increased INR and bleeding risk',\n    management: 'Monitor INR closely; adjust warfarin dose if needed',\n    evidence_level: 'B',\n    sources: ['Clinical studies']\n  },\n  {\n    drugs: ['digoxin', 'amiodarone'],\n    severity: 'major',\n    mechanism: 'P-glycoprotein inhibition increases digoxin levels',\n    effect: 'Digoxin toxicity risk',\n    management: 'Reduce digoxin dose by 50%; monitor levels closely',\n    evidence_level: 'A',\n    sources: ['Cardiovascular pharmacology']\n  },\n  {\n    drugs: ['theophylline', 'ciprofloxacin'],\n    severity: 'major',\n    mechanism: 'CYP1A2 inhibition reduces theophylline clearance',\n    effect: 'Theophylline toxicity with seizures possible',\n    management: 'Avoid combination or reduce theophylline dose significantly',\n    evidence_level: 'A',\n    sources: ['FDA', 'Clinical studies']\n  },\n  {\n    drugs: ['simvastatin', 'gemfibrozil'],\n    severity: 'major',\n    mechanism: 'Inhibition of simvastatin glucuronidation',\n    effect: 'Severe myopathy and rhabdomyolysis risk',\n    management: 'Avoid combination; use alternative statin if needed',\n    evidence_level: 'A',\n    sources: ['FDA warning']\n  },\n  {\n    drugs: ['phenytoin', 'carbamazepine'],\n    severity: 'moderate',\n    mechanism: 'Mutual CYP3A4 induction',\n    effect: 'Reduced efficacy of both anticonvulsants',\n    management: 'Monitor seizure control; may need dose adjustments',\n    evidence_level: 'B',\n    sources: ['Neurology guidelines']\n  },\n  {\n    drugs: ['lithium', 'hydrochlorothiazide'],\n    severity: 'major',\n    mechanism: 'Reduced lithium clearance',\n    effect: 'Lithium toxicity risk',\n    management: 'Monitor lithium levels frequently; adjust dose as needed',\n    evidence_level: 'A',\n    sources: ['Psychiatry guidelines']\n  },\n  {\n    drugs: ['metformin', 'contrast media'],\n    severity: 'major',\n    mechanism: 'Risk of lactic acidosis with renal impairment',\n    effect: 'Potentially fatal lactic acidosis',\n    management: 'Hold metformin 48h before and after contrast administration',\n    evidence_level: 'A',\n    sources: ['Radiology guidelines', 'FDA']\n  },\n  {\n    drugs: ['tacrolimus', 'fluconazole'],\n    severity: 'major',\n    mechanism: 'CYP3A4 inhibition increases tacrolimus exposure',\n    effect: 'Nephrotoxicity and immunosuppression',\n    management: 'Monitor tacrolimus levels; reduce dose significantly',\n    evidence_level: 'A',\n    sources: ['Transplant guidelines']\n  },\n  {\n    drugs: ['clopidogrel', 'omeprazole'],\n    severity: 'moderate',\n    mechanism: 'CYP2C19 inhibition reduces clopidogrel activation',\n    effect: 'Reduced antiplatelet efficacy',\n    management: 'Use pantoprazole instead; avoid omeprazole/esomeprazole',\n    evidence_level: 'B',\n    sources: ['FDA', 'Cardiology societies']\n  },\n  {\n    drugs: ['erlotinib', 'rifampin'],\n    severity: 'major',\n    mechanism: 'CYP3A4 induction reduces erlotinib exposure',\n    effect: 'Loss of therapeutic efficacy',\n    management: 'Avoid rifampin; use alternative anti-TB agent',\n    evidence_level: 'B',\n    sources: ['Oncology guidelines']\n  },\n  {\n    drugs: ['imatinib', 'ketoconazole'],\n    severity: 'moderate',\n    mechanism: 'CYP3A4 inhibition increases imatinib exposure',\n    effect: 'Increased toxicity risk',\n    management: 'Consider imatinib dose reduction; monitor closely',\n    evidence_level: 'B',\n    sources: ['Oncology studies']\n  },\n  {\n    drugs: ['pemetrexed', 'nsaids'],\n    severity: 'major',\n    mechanism: 'Reduced renal clearance of pemetrexed',\n    effect: 'Severe myelosuppression and mucositis',\n    management: 'Avoid NSAIDs 2 days before through 2 days after pemetrexed',\n    evidence_level: 'A',\n    sources: ['FDA label', 'Oncology guidelines']\n  },\n  {\n    drugs: ['capecitabine', 'phenytoin'],\n    severity: 'moderate',\n    mechanism: 'Increased phenytoin levels via DPD inhibition',\n    effect: 'Phenytoin toxicity',\n    management: 'Monitor phenytoin levels; consider dose reduction',\n    evidence_level: 'B',\n    sources: ['Oncology literature']\n  },\n  {\n    drugs: ['cyclophosphamide', 'allopurinol'],\n    severity: 'moderate',\n    mechanism: 'Enhanced bone marrow toxicity',\n    effect: 'Increased myelosuppression risk',\n    management: 'Monitor blood counts more frequently',\n    evidence_level: 'C',\n    sources: ['Oncology references']\n  },\n  {\n    drugs: ['docetaxel', 'ketoconazole'],\n    severity: 'major',\n    mechanism: 'CYP3A4 inhibition increases docetaxel exposure',\n    effect: 'Severe neutropenia and toxicity',\n    management: 'Avoid strong CYP3A4 inhibitors during treatment',\n    evidence_level: 'B',\n    sources: ['FDA label']\n  },\n  {\n    drugs: ['paclitaxel', 'carboplatin'],\n    severity: 'moderate',\n    mechanism: 'Sequence-dependent interaction',\n    effect: 'Enhanced myelosuppression if carboplatin given first',\n    management: 'Administer paclitaxel before carboplatin',\n    evidence_level: 'A',\n    sources: ['Clinical trials']\n  }\n];\n\nexport default FALLBACK_INTERACTIONS;"],"names":["FALLBACK_INTERACTIONS"],"mappings":"AACO,MAAMA,EAAwB,CACnC,CACE,MAAO,CAAC,UAAW,UAAU,EAC7B,SAAU,QACV,UAAW,8CACX,OAAQ,wCACR,WAAY,iEACZ,eAAgB,IAChB,QAAS,CAAC,sBAAuB,gBAAgB,CAAA,EAEnD,CACE,MAAO,CAAC,YAAa,cAAc,EACnC,SAAU,QACV,UAAW,iDACX,OAAQ,+CACR,WAAY,kDACZ,eAAgB,IAChB,QAAS,CAAC,KAAK,CAAA,EAEjB,CACE,MAAO,CAAC,WAAY,gBAAgB,EACpC,SAAU,QACV,UAAW,8CACX,OAAQ,uCACR,WAAY,qDACZ,eAAgB,IAChB,QAAS,CAAC,KAAK,CAAA,EAEjB,CACE,MAAO,CAAC,YAAa,YAAY,EACjC,SAAU,QACV,UAAW,2BACX,OAAQ,2BACR,WAAY,mDACZ,eAAgB,IAChB,QAAS,CAAC,uBAAuB,CAAA,EAEnC,CACE,MAAO,CAAC,WAAY,eAAe,EACnC,SAAU,WACV,UAAW,oDACX,OAAQ,kCACR,WAAY,sDACZ,eAAgB,IAChB,QAAS,CAAC,kBAAkB,CAAA,EAE9B,CACE,MAAO,CAAC,UAAW,YAAY,EAC/B,SAAU,QACV,UAAW,qDACX,OAAQ,wBACR,WAAY,qDACZ,eAAgB,IAChB,QAAS,CAAC,6BAA6B,CAAA,EAEzC,CACE,MAAO,CAAC,eAAgB,eAAe,EACvC,SAAU,QACV,UAAW,mDACX,OAAQ,+CACR,WAAY,8DACZ,eAAgB,IAChB,QAAS,CAAC,MAAO,kBAAkB,CAAA,EAErC,CACE,MAAO,CAAC,cAAe,aAAa,EACpC,SAAU,QACV,UAAW,4CACX,OAAQ,0CACR,WAAY,sDACZ,eAAgB,IAChB,QAAS,CAAC,aAAa,CAAA,EAEzB,CACE,MAAO,CAAC,YAAa,eAAe,EACpC,SAAU,WACV,UAAW,0BACX,OAAQ,2CACR,WAAY,qDACZ,eAAgB,IAChB,QAAS,CAAC,sBAAsB,CAAA,EAElC,CACE,MAAO,CAAC,UAAW,qBAAqB,EACxC,SAAU,QACV,UAAW,4BACX,OAAQ,wBACR,WAAY,2DACZ,eAAgB,IAChB,QAAS,CAAC,uBAAuB,CAAA,EAEnC,CACE,MAAO,CAAC,YAAa,gBAAgB,EACrC,SAAU,QACV,UAAW,gDACX,OAAQ,oCACR,WAAY,8DACZ,eAAgB,IAChB,QAAS,CAAC,uBAAwB,KAAK,CAAA,EAEzC,CACE,MAAO,CAAC,aAAc,aAAa,EACnC,SAAU,QACV,UAAW,kDACX,OAAQ,uCACR,WAAY,uDACZ,eAAgB,IAChB,QAAS,CAAC,uBAAuB,CAAA,EAEnC,CACE,MAAO,CAAC,cAAe,YAAY,EACnC,SAAU,WACV,UAAW,oDACX,OAAQ,gCACR,WAAY,0DACZ,eAAgB,IAChB,QAAS,CAAC,MAAO,sBAAsB,CAAA,EAEzC,CACE,MAAO,CAAC,YAAa,UAAU,EAC/B,SAAU,QACV,UAAW,8CACX,OAAQ,+BACR,WAAY,gDACZ,eAAgB,IAChB,QAAS,CAAC,qBAAqB,CAAA,EAEjC,CACE,MAAO,CAAC,WAAY,cAAc,EAClC,SAAU,WACV,UAAW,gDACX,OAAQ,0BACR,WAAY,oDACZ,eAAgB,IAChB,QAAS,CAAC,kBAAkB,CAAA,EAE9B,CACE,MAAO,CAAC,aAAc,QAAQ,EAC9B,SAAU,QACV,UAAW,wCACX,OAAQ,wCACR,WAAY,6DACZ,eAAgB,IAChB,QAAS,CAAC,YAAa,qBAAqB,CAAA,EAE9C,CACE,MAAO,CAAC,eAAgB,WAAW,EACnC,SAAU,WACV,UAAW,gDACX,OAAQ,qBACR,WAAY,oDACZ,eAAgB,IAChB,QAAS,CAAC,qBAAqB,CAAA,EAEjC,CACE,MAAO,CAAC,mBAAoB,aAAa,EACzC,SAAU,WACV,UAAW,gCACX,OAAQ,kCACR,WAAY,uCACZ,eAAgB,IAChB,QAAS,CAAC,qBAAqB,CAAA,EAEjC,CACE,MAAO,CAAC,YAAa,cAAc,EACnC,SAAU,QACV,UAAW,iDACX,OAAQ,kCACR,WAAY,kDACZ,eAAgB,IAChB,QAAS,CAAC,WAAW,CAAA,EAEvB,CACE,MAAO,CAAC,aAAc,aAAa,EACnC,SAAU,WACV,UAAW,iCACX,OAAQ,uDACR,WAAY,2CACZ,eAAgB,IAChB,QAAS,CAAC,iBAAiB,CAAA,CAE/B"}